Quote:

---

In an exploratory trial treating “long COVID” with the CCR5-binding antibody leronlimab, we observed significantly increased blood cell surface CCR5 in treated symptomatic responders but not in nonresponders or placebo-treated participants. These findings suggest an unexpected mechanism of abnormal immune downmodulation in some persons that is normalized by leronlimab.

---

I'm impatiently waiting for the peer reviewed journal article on long covid. I would bet my bottom dollar that the increase in CCR5 correlates to an increase in CD4 T-cells.